<DOC>
	<DOCNO>NCT01323205</DOCNO>
	<brief_summary>The purpose study explore safety , tolerability , potential clinical efficacy JNJ 40411813 schizophrenic patient .</brief_summary>
	<brief_title>Investigation Safety , Tolerability Potential Therapeutic Effects JNJ-40411813 Patients With Schizophrenia</brief_title>
	<detailed_description>This first-in-human study JNJ-40411813 schizophrenic patient currently receive antipsychotic drug treatment ( refer `` ( sub ) acute '' patient ) patient currently take antipsychotic drug treatment ( refer `` stable '' patient ) . The study consist 2 part : Part A Part B . Part A open-label ( patient know identity study treatment ) , ( sub ) acute schizophrenic patient receive monotherapy ( treatment one drug ) JNJ-40411813 . Part B double-blind ( patient study staff know identity study treatment ) randomize ( assign chance ) patient stable symptomatic schizophrenia receive treatment JNJ-40411813 placebo ( treatment identical appearance JNJ-40411813 contain active drug ) add-on therapy currently prescribe antipsychotic medication . Parts A ( JNJ-40411813 monotherapy ) B ( JNJ-40411813 add-on therapy ) run simultaneously . Patients take JNJ-40411813 placebo capsule orally ( mouth ) twice daily ( bid ) meal . Part A : Patients take JNJ-40411813 50 mg ( 1 capsule ) bid 150 mg ( 3 capsule ) bid 12 week . Part B : Patients take JNJ-40411813 50 mg bid placebo bid 4 week . After 4 week , dose JNJ-40411813 may increase 150 mg bid 6 week , patient assign placebo may take JNJ-40411813 50 mg bid 150 mg bid 10 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 35 kg/m2 inclusive Medically stable basis physical examination , medical history , vital sign , 12lead ECG clinical laboratory test In outpatient diagnose schizophrenia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) least 1 year prior screen . A current DSMIV axis I diagnosis schizophrenia Any medical condition could potentially alter absorption , metabolism , excretion study medication , Crohn 's disease , liver disease , renal disease Relevant history significant and/or unstable cardiovascular , respiratory , neurologic ( include seizure significant cerebrovascular disorder ) , renal , hepatic , endocrine , immunologic disease PANSS score &lt; 50 &gt; 120 Other significant and/or unstable systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>JNJ-40411813</keyword>
</DOC>